Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

Erlotinib has demonstrated poor clinical response rates for head and neck squamous cell carcinoma (HNSCC) to date and the majority of respondents acquire resistance to erlotinib relatively quickly. To elucidate novel pathways involved in erlotinib resistance, we compared the gene expression profiles...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanam, Aditya, Gibson-Corley, Katherine N., Love-Homan, Laurie, Ihejirika, Nnamdi, Simons, Andrean L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342798/
https://www.ncbi.nlm.nih.gov/pubmed/27738319
http://dx.doi.org/10.18632/oncotarget.12590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342798/
https://www.ncbi.nlm.nih.gov/pubmed/27738319
http://dx.doi.org/10.18632/oncotarget.12590

Ejemplares similares